Disclosed herein are pharmaceutical compositions comprising Abiraterone acetate and Darolutamide, which are useful in the treatment of a type of prostate cancer. The pharmaceutical composition possesses increased in- vitro permeability both in fasted and fed state which allows significant dose reduction and the abandoning of the requirement of taking the drugs on an empty stomach. Further disclosed are methods of formulating and manufacturing the pharmaceutical composition, its uses and methods of treatment using the pharmaceutical composition.
